Last reviewed · How we verify
Impetigo — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Altabax | RETAPAMULIN | Almirall | Pleuromutilin Antibacterial | 2007-01-01 | ||
| Ceftin | CEFUROXIME AXETIL | GSK | Cephalosporin Antibacterial | 1987-01-01 | ||
| Bactroban | MUPIROCIN | GSK | RNA Synthetase Inhibitor Antibacterial | Isoleucine--tRNA ligase, cytoplasmic | 1987-01-01 | |
| Zinacef | CEFUROXIME | GSK | Cephalosporin Antibacterial | Carbonic anhydrase 2 | 1983-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- GSK · 3 drugs in Impetigo
- Almirall · 1 drug in Impetigo
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Impetigo:
- Impetigo treatment updates — RSS
- Impetigo treatment updates — Atom
- Impetigo treatment updates — JSON
Cite this brief
Drug Landscape (2026). Impetigo — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/impetigo. Accessed 2026-06-10.
Related
- Impetigo full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing